Furthermore, our novel in vivo model of acquired resistance to CDK4/6i is unique, being characterized by tumor response to continuous CDK4/6 inhibition before the eventual emergence of resistance in the absence of new driver mutations. The gene discussed is CDK4; the disease is neoplasm.